Bavarian Nordic (OTCMKTS:BVNRY) Sees Unusually-High Trading Volume – Still a Buy?

Bavarian Nordic (OTCMKTS:BVNRY) saw unusually-high trading volume on Wednesday . 7,557 shares changed hands during trading, an increase of 117% from the previous session’s volume of 3,489 shares.The stock last traded at $9.52 and had previously closed at $9.6050.

Bavarian Nordic Stock Down 2.4%

The stock has a market cap of $2.26 billion, a price-to-earnings ratio of 12.53 and a beta of 1.20. The stock has a fifty day moving average of $9.59 and a two-hundred day moving average of $9.88.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $0.01 EPS for the quarter. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.32%. The firm had revenue of $165.70 million for the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.